DKFZp761E198 Inhibitors
The term DKFZp761E198 Inhibitors refers to a category of chemical compounds specifically designed and employed in the field of molecular biology and biochemistry. These inhibitors are utilized to modulate or interfere with the activity of a particular molecular target, often associated with the DKFZp761E198 gene or its encoded protein product. The class name implies a distinct focus on inhibitory actions within the context of experimental research. These inhibitors are valuable tools for scientists seeking to unravel the functional roles and regulatory mechanisms associated with the DKFZp761E198 gene or its related pathways.
The chemical structures and mechanisms of action of DKFZp761E198 Inhibitors can vary widely, depending on the specific research goals and the nature of the molecular target they are intended to interact with. These inhibitors are carefully designed to exert their effects in a controlled and selective manner, enabling researchers to investigate the biological processes in which the DKFZp761E198 gene or its products are involved. By perturbing the activity of the target molecule, scientists can gain insights into its function, signaling pathways, and potential interactions with other cellular components. In summary, DKFZp761E198 Inhibitors represent a specialized class of compounds instrumental in advancing our understanding of the molecular biology and biochemistry associated with the DKFZp761E198 gene, enabling researchers to dissect its roles and contributions within cellular systems
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits tyrosine kinase activity by binding to the ATP-binding site of BCR-ABL, a fusion protein responsible for chronic myeloid leukemia (CML). This disrupts downstream signaling pathways and suppresses cancer cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf and VEGFR, reducing tumor cell growth and angiogenesis. It also targets PDGFR and c-Kit, affecting various cancers, particularly kidney and liver cancers. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor, blocking phosphorylation of EGFR and downstream signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits BCR-ABL and Src family kinases, used in CML and Ph+ acute lymphoblastic leukemia (ALL). It also targets PDGFR and c-Kit, impairing their signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib targets EGFR, blocking its autophosphorylation and downstream signaling. It's used for NSCLC and pancreatic cancer thearpy, especially when EGFR is overexpressed. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual EGFR and HER2 tyrosine kinase inhibitor. It blocks phosphorylation and downstream signaling,. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, blocking protein degradation and causing apoptosis in multiple myeloma and mantle cell lymphoma cells. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mTOR, a key protein in the PI3K/AKT/mTOR pathway. This halts cell cycle progression and angiogenesis, used in various cancers, including renal cell carcinoma. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, blocking cell cycle progression in hormone receptor-positive breast cancer. It's often used in combination with hormonal therapy. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, interfering with B-cell signaling pathways. | ||||||